Sanofi Q2 2026: 17.8% Revenue Surge, New Drugs Fuel 10% Growth Outlook
Sanofi’s Q2 2026 results show a 17.8% sales jump, driven by Dupixent and new drugs, and a €2.09 EPS, prompting a 10% upward revenue outlook.
2 minutes to read
SANOFI
Sanofi Faces EU Probe Over Influenza Vaccine Marketing Claims
EU probes Sanofi over alleged misleading flu‑vaccine ads, risking up to 10% fine and impacting investor confidence. Learn how the case could reshape pharma marketing.
2 minutes to read